Incidence of psoriasis among adults in the United States: A sex- and age-adjusted population analysis.
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
24
03
2020
revised:
03
11
2020
accepted:
19
11
2020
pubmed:
1
12
2020
medline:
26
8
2021
entrez:
30
11
2020
Statut:
ppublish
Résumé
Information on recent trends in overall and subgroup incidences in psoriasis is limited. To estimate current incidence of psoriasis in the United States, compare incidences among demographic subgroups, and evaluate recent disease trends. Retrospective cohort analysis of psoriasis patients identified with electronic health records between 2014 and 2018. Incidence rate in the overall population (n = 2,152,192) was 63.8 (95% confidence interval [CI] 61.8-65.8) per 100,000 person-years. Incidence increased with age and peaked among individuals aged 70 to 79 years (92.3 [95% CI 85.1-100.0] per 100,000 person-years). Incidence was similar between men (62.8 [95% CI 59.8-65.9] per 100,000 person-years) and women (64.8 [95% CI 62.2-67.4] per 100,000 person-years). Standardized incidence rate for Whites (75.3 [95% CI 72.7-78.0] per 100,000 person-years) was greater than that for Hispanic/Latino patients (52.2 [95% CI 44.9-60.3] per 100,000 person-years; P < .001), patients of other race (54.3 [95% CI 46.5-62.9] per 100,000 person-years; P < .001), and Blacks (24.9 [95% CI 21.4-28.8] per 100,000 person-years; P < .001). Incidence appears to be stable within a recent 5-year period. Estimates were derived from approximately 15% of the health care-seeking US population. Psoriasis incidence in the United States appears to increase with age, is similar between sexes, and is greatest among Whites.
Sections du résumé
BACKGROUND
BACKGROUND
Information on recent trends in overall and subgroup incidences in psoriasis is limited.
OBJECTIVE
OBJECTIVE
To estimate current incidence of psoriasis in the United States, compare incidences among demographic subgroups, and evaluate recent disease trends.
METHODS
METHODS
Retrospective cohort analysis of psoriasis patients identified with electronic health records between 2014 and 2018.
RESULTS
RESULTS
Incidence rate in the overall population (n = 2,152,192) was 63.8 (95% confidence interval [CI] 61.8-65.8) per 100,000 person-years. Incidence increased with age and peaked among individuals aged 70 to 79 years (92.3 [95% CI 85.1-100.0] per 100,000 person-years). Incidence was similar between men (62.8 [95% CI 59.8-65.9] per 100,000 person-years) and women (64.8 [95% CI 62.2-67.4] per 100,000 person-years). Standardized incidence rate for Whites (75.3 [95% CI 72.7-78.0] per 100,000 person-years) was greater than that for Hispanic/Latino patients (52.2 [95% CI 44.9-60.3] per 100,000 person-years; P < .001), patients of other race (54.3 [95% CI 46.5-62.9] per 100,000 person-years; P < .001), and Blacks (24.9 [95% CI 21.4-28.8] per 100,000 person-years; P < .001). Incidence appears to be stable within a recent 5-year period.
LIMITATIONS
CONCLUSIONS
Estimates were derived from approximately 15% of the health care-seeking US population.
CONCLUSION
CONCLUSIONS
Psoriasis incidence in the United States appears to increase with age, is similar between sexes, and is greatest among Whites.
Identifiants
pubmed: 33253841
pii: S0190-9622(20)33081-4
doi: 10.1016/j.jaad.2020.11.039
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1023-1029Informations de copyright
Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest Dr Garg is an advisor for AbbVie, Amgen, Boehringer Ingelheim, Incyte, Janssen, Novartis, Pfizer, UCB, and Viela Bio, and receives research grants from AbbVie and the National Psoriasis Foundation. Authors Burshtein and Strunk have no conflicts of interest to declare.